A new research paper was published in Volume 12 of Oncoscience on October 14, 2025, titled "Bridging clinical insight and laboratory model in high-grade serous ovarian carcinoma (HGSOC) using DNA ...
Researchers say that in the course of developing a new model for ovarian cancer, they've developed additional evidence that serous uterine cancer possibly begins in the fallopian tubes, not the uterus ...
Most uterine cancers have excellent five-year survival rates—up to 95% for localized cancer. Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 cancer.
Figure 1: Hemocytometer dead cells count. Here is the bar graph showing the hemocytometer based dead cell counts for each treatment group across day 1, day 2 and day 4 (24 hours post treatment). The ...
Figure 1: Hemocytometer dead cells count. Here is the bar graph showing the hemocytometer based dead cell counts for each treatment group across day 1, day 2 and day 4 (24 hours post treatment). The ...
Homologous recombination deficiency (HRD) status and response to platinum-based chemotherapy and PARP inhibitors in Chinese patients with ovarian cancer.
New research yields a novel method to use ultrasound to enhance machine learning's ability to accurately diagnose -- or rule out -- ovarian cancer. Although ovarian cancer is the deadliest type of ...
Plant-derived cannabinoids appear effective against ovarian cancer cells in laboratory experiments. Research from Thailand reveals that cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results